Monoclonal antibodies that specifically recognize non-enzymatically glycated epitopes residing in albumin were used to measure levels of glycated albumin in the plasma of control and streptozotocin diabetic rats. Standard or sample was incubated with monoclonal antibody immobilized onto preactivated tubes, and binding was detected with enzyme-conjugated polyclonal antibody to rat albumin and substrate. Rat glycated albumin exhibited a linear dose response in the assay, and plasma samples contained between 30-100 ILg/ 50 ILL Levels were significantly increased in diabetic compared with control rats, and correlated positively and significantly with mean blood glucose concentrations measured in the fasting and fed states. The results indicate that glycated albumin levels measured by immunoassay reflect recent integrated glycaemia and provide an objective index of glycaemic status in the rat experimental model of diabetes.
Summary
Monoclonal antibodies that specifically recognize non-enzymatically glycated epitopes residing in albumin were used to measure levels of glycated albumin in the plasma of control and streptozotocin diabetic rats. Standard or sample was incubated with monoclonal antibody immobilized onto preactivated tubes, and binding was detected with enzyme-conjugated polyclonal antibody to rat albumin and substrate. Rat glycated albumin exhibited a linear dose response in the assay, and plasma samples contained between 30-100 ILg/ 50 ILL Levels were significantly increased in diabetic compared with control rats, and correlated positively and significantly with mean blood glucose concentrations measured in the fasting and fed states. The results indicate that glycated albumin levels measured by immunoassay reflect recent integrated glycaemia and provide an objective index of glycaemic status in the rat experimental model of diabetes.
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The experimentally diabetic rat is used extensively to study the influence of acquired hyperglycaemia and the effects of pharmacological, hormonal and nutritional manipulations on various aspects of diabetes, including pathophysiological changes relevant to the development of diabetic complications. Increasingly sophisticated parameters reflecting potential functional or structural damage in relevant organs have been studied, but assessment of the diabetic state and of the impact of therapeutic interventions on the glycaemic status continues to rest largely on occasional measurement of blood or urine glucose concentrations (Cohen & Khalifa 1977 , Cohen et a1. 1985 , Hostetter, Troy & Brenner 1981 , O'Donnell ei a1. 1988 , Scholey & Meyer 1989 , Zatz et a1. 1987 . Some
Correspondence to: Margo P. Cohen, MD, 3508 Market Street, Suite 420, Philadelphia, PA 19104, USA. Accepted 20 January 1993 studies have used glycohaemoglobin levels, performed with ion exchange or affinity chromatography minicolumns, to evaluate long-term glycaemic control, but few studies have examined interim hyperglycaemia on a regular basis (Cohen et al, 1985 , Soulis-Liparota et a1. 1991 , Cohen et a1. 1991a , 1991b . This consideration is important in view of the possibility that fluctuations in ambient glycaemia, independent of or resulting from therapeutic manipulations, may influence the outcome of the study. However, daily bleeding is laborious and urine collections may be unaesthetic, and a simple method to assess integrated glycaemic status with a single blood sampling on a weekly or bimonthly basis would be advantageous. Since the circulating half-life of albumin is estimated at about 13 days in man and about 4-6 days in the rat IGuthrow et a1. 1979 , Shima et al, 1991 , measurement of the amount of glycated albumin may fill this need. Albumin is the most abundant plasma protein, and glycated albumin accounts for about 80% of the glycated serum proteins.
We have described the production and characterization of a monoclonal antibody that was raised in mice immunized with non-enzymatically glycated human albumin, and the utilization of this antibody in an enzyme-linked immunosorbent assay to measure glycated albumin in human plasma (Cohen & Hud 1989a , 1989b . This antibody selectively recognizes glucose adducts in glycated albumin and does not react with non-glycated albumin or with other proteins, whether glycated or not. In the present study, we examined the immunoreactivity of this antibody with glycated lysine residues in rat albumin, and report herein a simple and immunospecific method for quantitation of glycated albumin in rat plasma. Results with this immunoassay correlate with results obtained by a more laborious method that utilizes separation on phenylboronate agarose, and show a positive and significant correlation with mean fasting and fed blood glucose concentrations.
Materials and methods

Enzyme immunosorbent assay
Monoclonal antibody All7 (5 J.tg) was immobilized onto preactivated, covalentlybinding polystyrene tubes (Alerchek, Portland, ME) with carbonate-bicarbonate coupling buffer, pH 9.6, for 18 h at room temperature. The tubes were blocked with 4% dried non-fat milk in glycine coupling buffer, pH 8.5, for 4 h at room temperature, and were stored until use at 4°C in glycine coupling buffer pH 7.2 containing 0.01 % milk and 0.02% Proclin [Rohm & Haas, Phila., PA) as preservative. To initiate the assay, the tubes were washed 3 times with wash buffer (O.OIM triethanolamine [TEA]; 0.15M NaClj 0.05% Tween 20; 0.02% Proclin, pH 6.8). Sample or standard (50 J.tl] was added to 500 J.tlreaction buffer (0.02% milk in PBS, pH 7.4), and the reaction was allowed to proceed for 60 min at room temperature. The tubes were then washed Neuman, Hud & Cohen 5 times with wash buffer, followed by incubation for 30 min with horse radish peroxidase (HRP)-conjugated second antibody (see below), diluted in 0.1M Tris, pH 7.5, containing 10% fetal calf serum. After washing, 500 J.tl of TMBlue (TSI, Inc., Milford, MA) were added, and the reaction was stopped after 10 min with 500 J.tlof 1M H2S04, Absorbances were read in a spectrophotometer at 450 nm, blanking the instrument against a zero tube in which the assay procedure had been performed but to which no standard or sample was added.
Samples consisted of rat plasma obtained by centrifugation of blood collected from the tail veins into EDTA-treated tubes. Standard for the rat glycated albumin assay was albumin obtained commercially (Sigma Chern. Co., St Louis, MO), which was found to contain 2-5% glycated albumin. The amount lJ.tg]of glycated albumin in the standard was determined by using a competitive immunoassay (ELISA) that is specific for rat albumin (see below) to measure albumin in the (glycated) fraction that adsorbed to a column of phenylboronate agarose (PBAj Isolab, Akron, OH) and was eluted with 100 mM sorbitol. Standard was also calibrated against authentic glycated rat albumin, purified by application to a column of phenylboronate agarose. Standards for the human glycated albumin assay consisted of a mixture of glycated and unglycated albumin, commercially obtained (Miles, Elkhart, IN), and purified by DEAEsepharose chromatography to remove contaminating substances and unidentified oligomers. The amount of glycated albumin (J.tg) in the standard was determined by calibration against authentic glycated albumin containing 1 mol of glucose per mol of albumin, which was purified from human plasma by sequential chromatography on Affi-gel blue and phenylboronate agarose (Cohen & Hud 1989a) . Second antibody for assay of rat standards and samples was HRP-conjugated sheep anti-rat albumin [1: 2000 dilution)j second antibody for assay of human standards was HRP-conjugated goat antihuman albumin (1: 3000 dilution), both from Cappel (West Chester, PA).
Affinity chromatography on phenylboronate agarose
Determination of rat glycated albumin by phenylboronate affinity chromatography was performed according to the procedure described by Silver et 01. (1991) , with some modifications. 501t1of rat plasma was mixed with 1501t1of equilibration buffer (250 mM ammonium acetate, 50 mM MgCl z , pH 8 . 5, containing O· 4% thimerosal) and loaded onto a O· 5 ml column of PBA, equilibrated in the same buffer but lacking the BSA. The nonadsorbed fraction was eluted by washing the column with 20 ml of the buffer; the adorbed (glycated) fraction was then eluted with 2 ml of the column buffer lacking MgCl z and containing 100 mM sorbitol.
Immunoassay of albumin
The amount of glycated albumin in the PBA-adsorbed fraction was determined in an ELISA for rat albumin (Exocell; Philadelphia, PAl. Total plasma albumin also was determined with this assay, in which antibody against rat albumin is immobilized onto microtitre wells and to which standard or sample are added with diluent to 100 p.l volume. After equilibration at room temperature for 20 min, rat albumin conjugated to HRP is added and the reaction allowed to proceed for 30 min at room temperature. Following washing several times with saline containing Tween 20, substrate colour developer [TMBlue) and then stopper are added, and the absorbances in the wells are read at 450 nm in an ELISA reader. The intra-and inter-assay coefficients of variation with this assay are less than 5%.
Experimental animals
Age-matched male Wistar rats (Charles River Laboratories) fed laboratory chow were housed in individual metabolic cages and provided water ad-libitum. One half of the animals received an intraperitoneal injection of streptozotocin (45 mg/kg), followed one week later by another intraperitoneal injection of 45 mg/kg. This schedule induces moderate 6S chronic hyperglycaemia, simulating the clinical condition in human Type II diabetes and [imperfectly) treated Type I diabetes (Cohen, Klepser & Wu 1991a . Further, the extreme hyperglycaemia resulting from a single injection of 65-85 mg/kg of streptozotocin produces severe catabolism and, frequently death of the animals if not treated with insulin. The other half of the animals received injections of vehicle alone. Animals weighed approximately 200 g at the time of injection. Rats were maintained for 4-8 weeks after injection. Fasting (8 h after morning removal of chow from cages) and fed (1 h after afternoon return of chow to cages) blood glucose concentrations were measured 2 weeks before and on the day of sampling for glycated albumin determinations.
Results
The underlying principle of the enzyme immunosorbent assay for glycated albumin resides in the highly specific nature of the A71? monoclonal antibody, which discriminates between glycated versus unglycated albumin and does not react with other plasma proteins, whether glycated or not (Cohen & Hud 1989aJ. Thus, when samples contain both unglycated and glycated albumin, only the glycated species react with the antibody; this binding is detected with a second antibody that is specific for albumin but does not discriminate between glycated versus unglycated forms (Cohen & Hud 1989b ). In the present study, the use of HRP-conjugated antibody against rat albumin as the second (detecting) antibody allowed measurement of the amount of glycated albumin in rat plasma by specific immunoassay. This is illustrated in Table I , which depicts assay results with glycated rat versus glycated human albumin, using anti-rat versus anti-human albumin HRPconjugate as second antibody. Rat glycated albumin that bound to the immobilized A71? monoclonal antibody did not react with the anti-human albumin second antibody; human glycated albumin that bound to the immobilized A?l? monoclonal in singlicate, with duplicate immunoassay analysis of the amount of albumin in the adsorbed (glycated) fraction. All total albumin levels were measured in duplicate by the competitive immunoassay. Results with each method expressed as per cent of total albumin that is glycated. Triangles = non-diabetic rats; circles = diabetic rats. r= 0.88 versus diabetic animals. Levels of rat plasma glycated albumin determined by the EIA correlated (1=0.88) with values estimated by adsorption to phenylboronate agarose (Fig 1) . Table 3 presents blood glucose concentrations and glycated albumin levels in the individual experimental animals. The diabetic animals exhibited marked hyperglycaemia in the fed state; most of the diabetic animals also had fasting hyperglycaemia. This hyperglycaemia was reflected in increased glycated albumin levels, measured by EIA, in the plasma of diabetic versus non-diabetic animals ( Table 3) . Glycated albumin correlated positively and significantly (r=O.93) with the mean blood glucose concentrations measured in fasting and fed samples 2 weeks before and the day of sampling for glycated albumin (Fig 2) .
Discussion
This study was prompted by the development of a monoclonal antibody that is highly specific for glycated epitopes residing in albumin and that does not recognize other Glycated albumin expressed as per cent; blood glucose expressed as mgldl and each point represents the mean derived from 4 determinations (2 fasting plus 2 fed) performed 2 weeks apart (see Table 3 ). Triangles=non-diabetic rats; circles = diabetic rats. r= 0.93 proteins, whether glycated or not rCohen &. Hud 1989a). The antibody was raised in mice immunized with glycated albumin purified from human plasma, but its ability to recognize an analogous epitope in rat albumin has not been previously examined. The demonstration of such reactivity would allow immunoassay of rat glycated albumin} a tool that could be useful for monitoring glycaemia in widely used, rat experimental models of diabetes. The primary requirement for epitopic recognition by the A717 monoclonal antibody appears to be the fructosyl-lysine adduct in lys-lys or lyshis sequence carried within a steric or conformational component specific to albumin. Albumin is a highly conserved molecule, and the glycatable residues of rat albumin have sequence homology with human albumin. In particular, the lysine 525 residue, which is the principal site undergoing glycation in vivo (Garlick &. Mazer 1983 , Iberg &. Fluckiger 1986 , is contained within identical sequences in rat and human albumin (Dugiaczyk et al. 1982 , Sargent et a1. 1981 ; namely, gln-ile-Iys-Iys-gln-thr-ala-leu.
The available literature indicates that short-to intermediate-term integrated glycaemia is best reflected by the level of glycated albumin (Winocur et al. 1989 , Rendall et ai. 1986 , Dolhofer & Wieland 1981 , Jones et al. 1986 , Kemp et al. 1984 , Leiper et al. 1985 . This reflects the circulating half-life of albumin and the observation that the extent of nonenzymatic glycation of circulating proteins is largely determined by the time-averaged glucose concentration to which the protein is exposed during its residence in the circulation (Bunn et al. 1976 , Koenig & Cerami 1980 ). In the present study, plasma glycated albumin levels measured by immunoassay correlated with mean glucose concentrations in the fasting and fed states over a 2-week interval. These findings suggest that, by providing an objective parameter of integrated glycaemia during the preceding 1-2 weeks, measurement of the extent of glycation of albumin in diabetic rats can afford convenient and timely assessment of the influence of therapeutic interventions on glycaemic status in this experimental model.
The methods that have been described to estimate human glycated albumin levels rely on separation of glycated from nonglycated plasma or serum proteins by affinity chromatography on phenylboronate (PBA) agarose and quantitation of the amount of albumin in the phenylboronate adsorbed (glycated) fraction by colorimetric or immunometric assay for albumin [Winocur et al. 1989 , Rendall et al. 1986 , Jones et al. 1986 , Kemp et al. 1984 , Leiper et al. 1985 , Austin et al. 1987 . We employed the latter approach for comparative analysis of rat plasma glycated albumin levels determined with the monoclonal antibody immunoassay versus the PBA method, finding a correlation coefficient of O· 88. However, glycated albumin levels measured with the monoclonal antibody assay were higher than those estimated after phenylboronate separation. The reason for this is unclear, but most likely relates to the different principles involved with the different assay procedures (i.e. affinity Neuman, Hud & Cohen binding versus monoclonal antibody immunoreactivity) and to the extensive sample manipulation required in the PBA method. Nevertheless, results with the described immunoassay, PBA affinity chromatography or densitometric scanning of agarose gel electrophoresis after PBA separation are within the same general range. This contrasts sharply with the high reference range for serum glycated rat or human albumin reported with the elaborate HPLC method described by Shima et al. (Shima et al. 1988 (Shima et al. , 1991 . The immunoassay for rat glycated albumin described herein can be completed in an hour and requires only a simple spectrophotometer for reading results. These features, and the high correlation between glycated albumin levels measured with the EIA and mean ambient glucose concentrations during a 2-week period, make the assay a favourable candidate for utilization in the research laboratory to conveniently monitor glycaemic status in rat experimental models of diabetes.
